Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deepak Bhatt

Interventional Cardiology New York, NY Medical Doctor

NPI 1962515551 CMS profile 1131143

1190 5Th Ave, New York, NY 10029

Open in the dashboard

General payments

$1,612,226

329 records reported · program years 2019–2025

Research payments

$141,972

Paid to them · 87 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,497,922 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Deepak Bhatt of New York, NY is reported in the CMS Open Payments database as having received $1,612,226 across 329 general payments and $141,972 in research payments paid to them. Separately, studies naming them as principal investigator received $2,497,922 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $540,549 106
2025 Research $19,965 13
2024 General $376,866 46
2024 Research $9,000 3
2023 General $174,617 36
2023 Research $20,800 8
2022 General $283,860 72
2022 Research $43,660 30
2021 General $164,443 25
2021 Research $16,671 11
2020 General $12,260 10
2020 Research $21,766 14
2019 General $59,630 34
2019 Research $10,111 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deepak Bhatt
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Deepak Bhatt were reported at $540,549. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Deepak Bhatt Interventional Cardiology median Middle half National median
2019 $59,630 $1,097 $329–$3,048 $163
2020 $12,260 $473 $161–$1,480 $114
2021 $164,443 $677 $233–$1,827 $132
2022 $283,860 $978 $333–$2,724 $149
2023 $174,617 $1,136 $382–$2,986 $160
2024 $376,866 $1,181 $395–$3,326 $164
2025 $540,549 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bristol-Myers Squibb Company $1,030,125 181 payments
  2. Pfizer Inc. $96,900 5 payments
  3. Janssen Research & Development, LLC $71,379 9 payments
  4. Boston Scientific Corporation $57,420 2 payments
  5. CSL Behring $49,970 23 payments
  6. Boehringer Ingelheim International GmbH $38,509 21 payments
  7. Sanofi US Services Inc. $33,749 9 payments
  8. Novo Nordisk AS $31,656 8 payments
  9. Boehringer Ingelheim Norway KS $31,170 1 payment
  10. AstraZeneca Pharmaceuticals LP $30,251 3 payments
  11. Other $141,097 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $867,519 43 payments
  2. Consulting Fee $492,689 77 payments
  3. Travel and Lodging $215,558 100 payments
  4. Food and Beverage $25,538 96 payments
  5. Education $7,588 11 payments
  6. Honoraria $2,085 1 payment
  7. Compensation for serving as faculty or as a speaker for a medical education program $1,250 1 payment
Products named General payments · program years 2019–2025
  1. XELJANZ $96,900 5 payments
  2. Clinical Trial Product $57,420 2 payments
  3. JARDIANCE Diabetes $37,296 9 payments
  4. PRADAXA $15,796 12 payments
  5. SOTAGLIFLOZIN $13,640 6 payments
  6. BRILINTA $11,575 7 payments
  7. Non-Covered $11,052 3 payments
  8. Kerendia $7,526 4 payments
  9. JARDIANCE Diabetes $5,565 1 payment
  10. Korlym $5,100 1 payment
  11. Other $8,874 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. CSL Behring $62,000 19 payments
  2. Pfizer Inc. $44,900 35 payments
  3. Novartis Pharma AG $18,004 12 payments
  4. Sanofi-Aventis U.S. LLC $7,345 15 payments
  5. Amgen Inc. $6,762 4 payments
  6. Regeneron Pharmaceuticals, Inc. $1,961 1 payment
  7. Daiichi Sankyo Inc. $1,000 1 payment

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$3,034

Medicare's payments for the services billed

Medicare patients

11

Average age 78

Services billed

44

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim RCV GmbH & Co KG $5,565
$5,565 — —
PRALUENT
  • SANOFI-AVENTIS U.S. LLC $750
$750 — —
Repatha
  • Amgen Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

416 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record